This brand name is authorized in Australia, Brazil, Cyprus, France, New Zealand, Spain, Tunisia.
The drug DAONIL contains one active pharmaceutical ingredient (API):
1
|
UNII
SX6K58TVWC - GLYBURIDE
|
|
Glibenclamide, a second-generation, short half-life sulphonylurea, is a hypoglycaemic agent that reduces blood-glucose by stimulating insulin release by the pancreas. Sulphonylureas act on pancreatic beta-cells by inhibiting ATP-sensitive potassium channels. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| A10BB01 | Glibenclamide | A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BB Sulfonamides, urea derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| AU | Pharmaceutical Benefits Scheme | 2939Q |
| BR | Câmara de Regulação do Mercado de Medicamentos | 576720080083617 |
| ES | Centro de información online de medicamentos de la AEMPS | 48545 |
| FR | Base de données publique des médicaments | 64823509 |
| NZ | Medicines and Medical Devices Safety Authority | 1192 |
| TN | Direction de la Pharmacie et du Médicament | 9103211A, 9103211B, 9263341, 9263342 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.